Previous 10 | Next 10 |
Otonomy, Inc. (NASDAQ: OTIC) reported that the OTO-313 Phase 2 trial in tinnitus demonstrated no meaningful benefit versus placebo for primary and secondary endpoints across all timepoints. The phase 2 trial enrolled 153 patients with unilateral, persistent tinnitus of a...
Gainers: Virax Biolabs ( VRAX ) +62% . Aethlon Medical ( AEMD ) +46% . GeoVax Labs ( GOVX ) +46% . Celyad Oncology ( CYAD ) +40% . Outset Medical ( OM ) +28% . Losers: Otonomy ( OTIC ) -77% . Kazia Therapeu...
The shares of neurology focused Otonomy ( NASDAQ: OTIC ) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These ...
Otonomy ( OTIC ) -68% reports results from Phase 2 clinical trial of OTO-313 in patients with Tinnitus. Kazia Therapeutics ( KZIA ) -47% . Senti Biosciences ( SNTI ) -18% . FaZe Holdings ( FAZE ) -17% . Beam Therapeutics ( BEAM )...
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints Company to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 foll...
Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q2 2022 Earnings Call Jul 25, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q2 2022 Earnings Call Transcript
Otonomy, Inc. (OTIC) Q2 2022 Earnings Conference Call July 25, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke Dave Weber - Chief Executive Officer, President and Board Member Paul Cayer - Chief Financial and Business Officer ...
Otonomy press release ( NASDAQ: OTIC ): Q2 GAAP EPS of -$0.19 beats by $0.01 . Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Gui...
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022 Positive top-line results announc...
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...